众生药业：昂拉地韦片的两项III期临床试验设计为每日用药1次，共服药5天，目前均已完成所有参与者入组

Group 1 - The company has completed participant enrollment for two Phase III clinical trials of Arbidol, targeting adolescents aged 12-17 and children aged 2-11 with uncomplicated influenza A [1] - The design of both Phase III clinical trials involves administering the drug once daily for five days [1] - The company is set to proceed with the project development work in an orderly manner [1]